MH
CBPO

Mason Hawkins’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Mason Hawkins’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,645
Closed -$287K – 35
2017
Q4 		$287K Buy
+3,645
New +$303K ﹤0.01% 31

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.55B AUM 11.62% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mason Hawkins's CBPO Position: Q1 2018 in Review

Mason Hawkins sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2018, closing a stake of 3,645 shares — an estimated $287K sold.

Mason Hawkins first reported a position in CBPO in Q4 2017 and held it in 1 quarter. The position peaked at $287K in Q4 2017. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2018.

  • Mason Hawkins reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2018 after selling out during the quarter.
  • Mason Hawkins sold 3,645 China Biologic Products Holdings, Inc. shares in Q1 2018, an estimated $287K.
  • Mason Hawkins first reported a position in China Biologic Products Holdings, Inc. in Q4 2017 and held it in 1 quarter.
  • Mason Hawkins's China Biologic Products Holdings, Inc. position peaked at $287K in Q4 2017.
  • 86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2018.

Based on Southeastern Asset Management's 13F filing for Q1 2018, filed 15 May 2018.